A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Sequence similarity === EC categories do not reflect sequence similarity. For instance, two ligases of the same EC number that catalyze exactly the same reaction can have completely different sequences. Independent of their function, enzymes, like any other proteins, have been classified by their sequence similarity into numerous families. These families have been documented in dozens of different protein and protein family databases such as Pfam.
Hand therapy is often recommended. Approximately six weeks after surgery the patient is able completely to use the hand. The average recurrence rate is 39% after a fasciectomy after a median interval of about four years.
== Collagen and accessory proteins == Almost all of the organic (non-mineral) component of bone is dense collagen type I, which forms dense crosslinked ropes that give bone its tensile strength. By mechanisms still unclear, osteoblasts secrete layers of oriented collagen, with the layers parallel to the long axis of the bone alternating with layers at right angles to the long axis of the bone every few micrometers. Defects in collagen type I cause the commonest inherited disorder of bone, called osteogenesis imperfecta. Minor, but important, amounts of small proteins, including osteocalcin and osteopontin, are secreted in bone's organic matrix. Osteocalcin is not expressed at significant concentrations except in bone, and thus osteocalcin is a specific marker for bone matrix synthesis. These proteins link organic and mineral component of bone matrix. The proteins are necessary for maximal matrix strength due to their intermediate localization between mineral and collagen. However, in mice where expression of osteocalcin or osteopontin was eliminated by targeted disruption of the respective genes (knockout mice), accumulation of mineral was not notably affected, indicating that organization of matrix is not significantly related to mineral transport.
== Characteristics == Krypton is characterized by several sharp emission lines (spectral signatures) the strongest being green and yellow. Krypton is one of the products of uranium fission. Solid krypton is white and has a face-centered cubic crystal structure, which is a common property of all noble gases (except helium, which has a hexagonal close-packed crystal structure).
Sources: en.wikipedia.org
Top-grain leather includes the outer layer of the hide, known as the grain, which features finer, more densely packed fibers, resulting in strength and durability. Depending on thickness, it may also contain some of the more fibrous under layer, known as the corium. Types of top-grain leather include: Full-grain leather contains the entire grain layer, without any removal of the surface. Rather than wearing out, it develops a patina during its useful lifetime. It is usually considered the highest quality leather. Furniture and footwear are often made from full-grain leather. Full-grain leather is typically finished with a soluble aniline dye. Russia leather is a form of full-grain leather. Corrected grain leather has the surface subjected to finishing treatments to create a more uniform appearance. This usually involves buffing or sanding away flaws in the grain, then dyeing and embossing the surface. Nubuck is top-grain leather that has been sanded or buffed on the grain side to give a slight nap of short protein fibers, producing a velvet-like surface. Split leather is created from the corium left once the top-grain has been separated from the hide, known as the drop split. In thicker hides, the drop split can be further split into a middle split and a flesh split. Bicast leather is split leather that is coated with a layer of polyurethane or vinyl with an embossed texture. This gives it the appearance of a grain. It is slightly stiffer than top-grain leather but has a more consistent texture.
Gastrointestinal Distress (nausea, vomiting, diarrhea, and oral ulcerations). Central Nervous System: Seizures, tremors, muscular twitching, confusion, agitation, ataxia, and hallucinations. Skin reactions Hepatotoxicity Infertility Hair Loss
=== Lima Group === With Castillo taking a more pro-Venezuela stance, many thought that Peru would leave the Lima Group, a consortium of countries with the goal of aiding the Venezuelan opposition. Starting 6 August 2021, Venezuelan and Cuban state media started claiming that Peru had left the Lima Group. While foreign media had announced Peru's exit, there was no word from the Peruvian government, which left many confused. Furthermore, Luis Arce, the President of Bolivia, celebrated Peru's supposed departure from the Lima Group. There was still no word from the Castillo Administration. However, Peru's departure from the Lima Group had been seemingly confirmed by Free Peru's General Secretary, Vladimir Cerrón. As a result, domestic media and Congress was left unsure on whether Peru had left the organization or not. Eventually, members of Congress sent forward a motion to confirm Peru's status in the Lima Group. After a while, Prime Minister Bellido confirmed that Peru had not left the Lima Group, claiming that the issue had not been formally discussed. However, Bellido also mentioned that the Foreign Ministry was evaluating Peru's status in the Lima Group. As of 20 September 2021, the permanent representative of Peru to the OAS has stated that the Lima Group "does not exist, because it has completed its cycle." Later, the Vice Foreign Minister pointed out "The Lima Group is a mechanism, it is not an international organization, and therefore mechanisms work when they need to work.
== Awards and honors == Arthur C. Cope Scholar Award (2024) from the American Chemical Society for his foundational contributions to organic chemistry. Cathay Award (2024) from the Chinese Peptide Society for his work in peptide science. Max Bergmann Kreis Gold Medal (2011) for outstanding contributions in peptide chemistry. Vincent du Vigneaud Award (2010) from the American Peptide Society.
The manufacture of antidotes called mithridate or theriac (English "treacle") continued into the nineteenth century. Ephraim Chambers, in his 1728 Cyclopaedia, says "Mithridate is one of the capital Medicines in the Apothecaries Shops, being composed of a vast Number of Drugs, as Opium, Myrrh, Agaric, Saffron, Ginger, Cinnamon, Spikenard, Frankincense, Castor, Pepper, Gentian, &c. It is accounted a Cordial, Opiate, Sudorific, and Alexipharmic". Petrus Andreas Matthiolus considered it more effectual against poisons than Venice treacle, and easier to make. Late versions of the antidote incorporated dried blood or the dried flesh of lizards or vipers or Malabathrum.
Sources: en.wikipedia.org
== History == The varicella-zoster vaccine is made from the Oka/Merck strain of live attenuated varicella virus. The Oka virus was initially obtained from a child with natural varicella, introduced into human embryonic lung cell cultures, adapted to and propagated in embryonic guinea pig cell cultures, and finally propagated in a human diploid cell line originally derived from fetal tissues (WI-38). Takahashi and his colleagues used the Oka strain to develop a live attenuated varicella vaccine in Japan in the early 1970s. This strain was further developed by pharmaceutical companies such as Merck & Co. and GlaxoSmithKline. American vaccinologist Maurice Hilleman's team at Merck then used the Oka strain to prepare a chickenpox vaccine in 1981. Japan was among the first countries to vaccinate for chickenpox. The vaccine developed by Hilleman was first licensed in the United States in 1995. Routine vaccination against varicella zoster virus is also performed in the United States, and the incidence of chickenpox has been dramatically reduced there (from four million cases per year in the pre-vaccine era to approximately 390,000 cases per year as of 2014). As of 2019, standalone varicella vaccines are available in all 27 European Union member countries, and 16 countries also offer a combined measles, mumps, rubella, and varicella vaccine (MMRV).
Mevalonate synthesis begins with the beta-ketothiolase-catalyzed Claisen condensation of two molecules of acetyl-CoA to produce acetoacetyl CoA. The following reaction involves the joining of acetyl-CoA and acetoacetyl-CoA to form HMG-CoA, a process catalyzed by HMG-CoA synthase. In the final step of mevalonate biosynthesis, HMG-CoA reductase, an NADPH-dependent oxidoreductase, catalyzes the conversion of HMG-CoA into mevalonate, which is the primary regulatory point in this pathway. Mevalonate serves as the precursor to isoprenoid groups that are incorporated into a wide variety of end-products, including cholesterol in humans.
John D. Rockefeller Sr. first conceived the idea of the foundation in 1901. In 1906, Rockefeller's business and philanthropic advisor, Frederick Taylor Gates, encouraged him toward "permanent corporate philanthropies for the good of Mankind" so that his heirs should not "dissipate their inheritances or become intoxicated with power." In 1909 Rockefeller signed over 73,000 Standard Oil shares worth $50 million, to his son, Gates and Harold Fowler McCormick as the third inaugural trustee, in the first installment of a projected $100 million endowment. The nascent foundation applied for a federal charter in the US Senate in 1910, with at one stage Junior even secretly meeting with President William Howard Taft, through the aegis of Senator Nelson Aldrich, to hammer out concessions. However, because of the ongoing (1911) antitrust suit against Standard Oil at the time, along with deep suspicion in some quarters of undue Rockefeller influence on the spending of the endowment, the result was that Senior and Gates withdrew the bill from Congress in order to seek a state charter from New York.
Sivasankar and his research team have found that the mechanism behind the puzzling phenomenon is due to long-lived, force-induced hydrogen bonds. Using data from previous experiments, the team used molecular dynamics to discover that two rod-shaped cadherins in an X-dimer formed catch bonds when pulled and in the presence of calcium ions. The calcium ions keep the cadherins rigid, while pulling brings the proteins closer together, allowing for hydrogen bonds to form. The mechanism behind catch bonds helps to explain the biophysics behind cell-cell adhesion. According to the researchers, "Robust cadherin adhesion is essential for maintaining the integrity of tissue such as the skin, blood vessels, cartilage and muscle that are exposed to continuous mechanical assault." The above catch bonds are formed between adhesion receptors and ligands, and among structural molecules and motor proteins, which bear force or generate force in their physiological function. An interesting recent development is the discoveries of catch bonds formed between signaling receptors and their ligands. These include bonds between T cell antigen receptors (TCR) or pre-TCR and peptide presented by major histocompatibility complex (pMHC) molecules, Fc gamma receptor and IgG Fc, and notch receptor and ligands. The presence of catch bonds in the interactions of these signaling (rather than adhesion) receptors have been suggested to be indicative of a possible role of these receptors as mechanoreceptors.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.